About us How we support you NATIONAL INSTITUTE for HEALTH & CARE EXCELLENCE (NICE) Melanoma UK is a NICE stakeholder and actively participates in any consultations linked to Melanoma and Non-Melanoma Skin Cancer. The most recent NICE Appraisal is NICE recommends pembrolizumab as an option for stage 2b and 2c melanoma patients